The Looming Threat of Geopolitical Risk in Clinical Supply Chains

Clinical supply chains are facing enormous geopolitical risk. For sponsors running global multicentre studies, disruptions linked to trade policy, conflict, and regulatory divergence are shaping drug development timelines. Pharma leaders must embed supply chain resilience into clinical portfolio planning to ensure that clinical development can withstand shocks without compromising patient safety or trial integrity.

Image

Vulnerabilities Threaten Clinical Trial Success

From trade restrictions to regional conflicts, global shocks threaten clinical trial continuity, drug distribution, and patient access.

Clinical trial supply chains are inherently complex. They must deliver investigational medicinal products across multiple geographies, often under strict temperature controls. All while meeting regulatory requirements.

Several factors amplify vulnerability in clinical trial supply chains. These areas of weaknesses in clinical trial supply chains mean that even minor geopolitical disruptions can cascade into significant delays.

1. The globalised of nature of pharma manufacturing

Active pharmaceutical ingredients (APIs) and finished products are frequently produced in a limited number of regions, creating dependency on specific countries.

2. Just-in-time logistics

Lean inventory strategies reduce cost but leave little buffer against disruption.

3. Regulatory fragmentation

Each region or country imposes its own requirements for importation, labelling, and distribution, increasing operational friction.

The Expanding Scope of Geopolitical Risk in Clinical Supply Chains

The nature of geopolitical risk has evolved beyond traditional trade barriers.

Today’s clinical supply chains must navigate:

• Export controls and sanctions
• Sudden tariff changes
• Border closures and customs delays
• Regional conflicts affecting transport routes
• Diverging regulatory standards across jurisdictions

The COVID-19 pandemic demonstrated how quickly global supply chains can be disrupted.

Subsequent geopolitical tensions have reinforced that these risks are not temporary.

The key sources of geopolitical disruption in clinical trial supply chains in a post-pandemic world include:

• Trade Restrictions: Tariffs and export bans limit access to critical APIs and biologics.
• Regional Conflicts: War zones disrupt logistics corridors.
• Sanctions: Pharmaceutical companies face compliance challenges when sourcing materials from restricted regions.
• Global Shocks: Events such as pandemics or energy crises amplify vulnerabilities in already fragile supply chains.

Clinical Trial Supply Chains Are Especially Exposed to Geopolitical Risk

Unlike commercial supply chains, clinical trial supply cannot easily absorb disruption.

Investigational medicinal products are often produced in limited quantities, manufacturing runs are tightly scheduled, and replacement stock is not readily available.

In addition, patient dosing schedules must be maintained precisely. Delays in clinical trial supply can lead to study protocol deviations, data loss, or even early study termination.

This makes clinical supply chains more sensitive to geopolitical disruption than their commercial counterparts.

Where Geopolitical Risk Has the Greatest Impact on Clinical Supply Chains

Geopolitical instability affects every stage of clinical development:

• Trial Continuity: Site closures or patient displacement interrupt recruitment and data collection.
• Manufacturing: Disrupted access to raw materials delays drug production.
• Cold Chain Logistics: Energy shortages or transport restrictions compromise temperature-sensitive shipments.
• Regulatory Coordination: Divergent national policies complicate global trial harmonisation.

Geopolitical risk affects multiple points in the supply chain.

These vulnerabilities are interconnected. A disruption in one area often propagates across the system.

1. Manufacturing Concentration

Dependence on single-region manufacturing creates a single point of failure.

2. Distribution networks

Air freight restrictions, port congestion, and customs delays can extend delivery timelines unpredictably.

3. Regulatory barriers

Changes in import/export requirements can halt shipments even when product is available.

4. Ancillary supplies

Clinical trials depend not only on the supply of investigational medicinal product but also on comparators, lab kits, and packaging materials. Disruption in any component can affect the entire study.

Image

From Efficiency to Resilience in Clinical Supply Chains

Historically, clinical supply chains were optimised for efficiency because cost reduction and lean operations were prioritised.

That model is no longer sufficient in today’s geopolitical landscape.

Resilience requires a different approach by addressing the key factors of:

• Redundancy in manufacturing and sourcing
• Strategic inventory buffers
• Flexible distribution networks
• Scenario planning for disruption

This shift from efficiency to resilience in clinical supply chains involves trade-offs.

Increased resilience often comes with higher upfront cost.

However, the cost of disruption is significantly higher.

The Role of Data and Predictive Planning in Reducing Geopolitical Risks 

Modern clinical trial supply chain management is increasingly data-driven.

Predictive analytics can identify potential clinical trial disruption risks before they materialise.

Additionally, scenario modelling allows organisations to evaluate the impact of different geopolitical events, and real-time tracking systems provide visibility into shipment status and delays.

These capabilities enable proactive rather than reactive clinical trial supply chain management.

The challenge is integration. Data must be consolidated across suppliers, logistics providers, and internal systems to create a unified view.

Image

Regulatory Complexity Is Increasing in Clinical Trial Supply Chains

Geopolitical fragmentation is also affecting regulatory environments.

Different regions are introducing divergent requirements for:

• Labelling and packaging
• Quality documentation
• Import/export approvals
• Pharmacovigilance reporting

For global trials, this increases the operational burden and the risk of non-compliance.

The International Council for Harmonisation continues to promote standards for harmonisation, but regional divergence remains a reality.

On the other hand, regulatory bodies can provide guidance during disruption, permitting reasonable modifications. 

Regulation exists to help coordinate adaptive protocols and compliance frameworks to maintain trial integrity during disruptions.

Where Leading Pharma Organisations Are Succeeding

Pharmaceutical companies that are managing geopolitical risk effectively share several characteristics.

One of the first capabilities that successful pharma companies deploy is the ability to map their supply chains in detail, including upstream dependencies such as raw materials and key starting materials.

This provides them the insight needed to successfully diversify suppliers and manufacturing locations where feasible.

Their clinical operations and regulatory strategy are fully integrated with supply chain planning. 

The digital tools they’ve prioristised spending on provide real-time visibility and predictive insight.

Altogether, these capabilities transform supply chains from reactive functions into strategic assets.

Strategies for clinical supply chain resilience that are working

Effective strategies for mitigating geopolitical risk in clinical trial supply chains include:

• Diversifying Suppliers: Avoiding reliance on single regions for critical inputs.
• Building Redundancy: Establishing backup manufacturing and distribution hubs.
• Scenario Planning: Using predictive analytics to model disruption impacts.
• Regulatory Engagement: Coordinating with agencies to adapt protocols during crises.

What Pharma Leaders Should Do Now to Mitigate Geopolitical Risk in Clinical Supply Chains

Addressing geopolitical risk in clinical trial supply chains requires coordinated action.

This action should start with end-to-end supply chain mapping.

Identify single points of failure across manufacturing, distribution, and ancillary supply.

Where critical dependencies exist, develop alternative sourcing or manufacturing options. Prioritise diversification.

Scenario planning can be used to model potential disruption events and define response strategies in advance.

This will help you align functions. Supply chain, clinical operations, and regulatory teams must operate with shared visibility and objectives.

Conclusion: Resilience Is a Competitive Advantage

Geopolitical risk in clinical supply chains is a feature of the current global financial and political landscape.

Clinical supply chains depend on cross-border logistics, specialised manufacturing hubs, and cold chain distribution.

Political instability, sanctions, and trade disputes can delay shipments, restrict access to raw materials, and increase costs. For sponsors, these disruptions translate into trial delays or clinical development failure.

The organisations that adapt to the risk of geopolitical disruption will be those that build resilience into their operating models, even at the cost of short-term efficiency.

Those that do not build resilience into their clinical trial supply chains risk study delays, increased costs, and compromised research outcomes.

Pharmatica provides the strategic insight needed for pharmaceutical leaders to navigate supply chain disruption and maintain trial continuity in an increasingly complex global landscape. Pharmatica helps connect supply chain risks to real-world clinical trial operations, allowing you to plan, adapt, and deliver with clarity.

Pharmatica: Insight. Connection. Impact.